The medicine is applied in addressing situations where symptoms are related to systemic imbalance from inadequate natural Growth Hormone (GH) levels. It addresses systemic deficits that lead to specific physical, developmental, and metabolic problems. The medication is considered relevant for the management of these hormone deficiencies.

---

Therapeutic Uses and Patient Benefits

Saizen is commonly used in pediatric patients to manage inadequate linear growth and short stature caused by conditions such as Childhood-onset GHD, Turner Syndrome, short stature in children born small for gestational age (SGA), and growth failure related to Chronic Kidney Disease (CKD). Its use may assist with supporting linear growth by addressing the symptomatic deficit.

In adult patients with verified GHD, the therapy plays a role in managing symptoms related to systemic imbalance, contributing to easing the effects of adverse body composition (decreased lean body mass and increased fat mass), and may help with managing associated fatigue. Saizen also assists in mitigating symptoms of severe muscle wasting or cachexia (e.g., associated with HIV/AIDS) and may assist with supporting nutrient absorption in certain patients with Short Bowel Syndrome.

“The goal is to provide supportive relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Body Composition Deficits Saizen is applied in addressing the symptom cluster of decreased lean body mass and increased fat mass in adults with GHD, contributing to improved physical function.

Official Eligibility and Contraindications

Saizen is permitted for use in pediatric patients with diagnosed Growth Hormone Deficiency (GHD), Turner Syndrome, short stature due to Chronic Renal Failure, or those born Small for Gestational Age (SGA) who fail to show catch-up growth. It is also approved for adult patients with confirmed GHD of either childhood or adult onset.

Absolute Contraindications

The medicine is contraindicated and must not be used in the presence of active malignancy or any evidence of tumor activity. It is also prohibited in patients with acute critical illness following major surgery, severe trauma, or acute respiratory failure. Further exclusions include patients with closed epiphyses (for growth promotion), active proliferative or severe non-proliferative diabetic retinopathy, or a known hypersensitivity to somatropin. Pediatric patients with Prader-Willi syndrome who have severe respiratory impairment or are severely obese are contraindicated.

Eligibility Restrictions

Use is restricted in several populations. In children with Chronic Renal Failure, treatment must be discontinued upon renal transplantation. A lower starting dose and cautious titration are recommended for older patients due to increased sensitivity. The medicine is not recommended during pregnancy due to a lack of human data.

Saizen (somatropin) is a hormonal product, and its interactions are primarily mediated through its effects on various metabolic and endocrine pathways. Concomitant use with several classes of medications requires careful monitoring and potential dose adjustment by a healthcare provider.

Interacting Medicine Categories

Category	Documented Interaction Basis	Required Action
Glucocorticoids	Somatropin inhibits the 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD-1) enzyme, potentially reducing active cortisol levels.	Patients on replacement therapy may require higher maintenance doses of glucocorticoids (e.g., cortisone acetate, prednisone) to prevent hypoadrenalism.
Antihyperglycemic Agents	Somatropin can decrease glucose tolerance and may elevate blood sugar levels.	Doses of concurrent insulin and/or oral/injectable hypoglycemic agents may need adjustment.
Oral Estrogen	Oral estrogen can reduce the effectiveness of somatropin.	Women using oral estrogen replacement therapy may require larger doses of Saizen to achieve therapeutic goals.
Thyroid Hormones	Somatropin may increase the extra-thyroid conversion of T4 to T3.	Unmasking of central hypothyroidism or worsening of existing hypothyroidism may occur, requiring thyroid hormone replacement adjustment.
CYP450-Metabolized Drugs	Somatropin may alter the clearance of compounds metabolized by liver cytochrome P450 (CYP450) enzymes.	Careful monitoring is advised for patients taking drugs primarily cleared via CYP450 pathways, such as corticosteroids and sex steroids.

Saizen (somatropin) is a polypeptide hormone that is structurally and functionally analogous to endogenous human growth hormone (hGH). Its mechanism of action begins with binding to specific growth hormone receptors (GHRs), which are expressed on the surface of various cell types, with high density in hepatocytes.

This ligand-receptor interaction triggers a complex intracellular signaling cascade, primarily the activation of the JAK-STAT pathway. Activation of this pathway leads to the gene expression and subsequent release of Insulin-like Growth Factor-1 (IGF-1) and its corresponding binding proteins. IGF-1 acts as the principal mediator of Saizen’s systemic effects, binding to the IGF-1 receptor (IGF-1R) to modulate cellular proliferation, differentiation, and overall metabolism.

At the cellular level, the resulting pathway activity facilitates the transport of amino acids, promotes protein synthesis, and mobilizes lipids for energy substrate, leading to a net positive nitrogen balance. This cascade of events culminates in anabolic effects on both bone and muscle tissue across multiple organ systems.

Administration Overview

Saizen is typically administered via subcutaneous injection, which involves delivering the medication into the fatty tissue layer just beneath the skin. This method allows for steady absorption of the growth hormone into the bloodstream.

Preparation for Use

Before administration, the medication must be prepared according to the specific format provided, such as a vial for reconstitution or a pre-filled cartridge. It is important to ensure that the solution is clear and free of particles. If the medication requires mixing, it should be swirled gently rather than shaken to maintain the integrity of the protein structure.

Injection Sites

Common areas for subcutaneous injection include:

• Abdomen: Avoiding the area immediately surrounding the navel.
• Thighs: The outer front portion of the upper thighs.
• Buttocks: The upper outer quadrant.
• Upper Arms: The fleshy back part of the arm.

To prevent localized tissue changes, such as the thinning or thickening of fat (lipoatrophy or lipohypertrophy), it is standard practice to rotate injection sites daily. A new injection should be at least one inch away from the previous site.

Using Delivery Devices

Saizen is often used in conjunction with specific delivery systems designed for patient ease. These may include mechanical injection pens or electronic delivery devices. These tools are engineered to provide precise measurements and may offer features like hidden needles or injection logs to help monitor the routine.

Timing and Routine

Growth hormone is generally administered in the evening. This timing is intended to mimic the body’s natural physiological rhythm, as the pituitary gland normally releases peak amounts of growth hormone during sleep. Maintaining a consistent daily schedule helps ensure a steady level of the medication in the body.

Research Evidence / Overview of Studies for Saizen (Somatropin)

Evidence for Use in Pediatric Growth Hormone Deficiency (GHD)

Research exploring the use of Saizen in children and adolescents with Growth Hormone Deficiency ( GHD) primarily relies on a combination of short-term Randomized Controlled Trials ( RCTs) and extensive, long-term observational registries. These studies were used in research exploring how growth patterns change over time, applying measurements related to physical development and systemic function. The primary metrics assessed were linear growth measures, including Height Velocity ( HV) and changes in Height Standard Deviation Score ( HtSDS). Follow-up durations were limited in the initial RCTs. The research uses observational registries to gather data on final adult height. Long-term effects, particularly outcomes extending decades into adult life, are not fully established.

Evidence for Use in Growth Failure Related to Turner Syndrome and SGA

Somatropin was also evaluated in research exploring growth patterns associated with specific genetic and developmental conditions. This includes girls with Turner Syndrome ( TS) and children who were born Small for Gestational Age ( SGA) but failed to achieve spontaneous catch-up growth. These studies explored growth patterns in conditions characterized by functional limitations. Research examined the attainment of final adult height and catch-up growth rate for SGA populations. Findings help contextualize how growth failure is measured in these patient groups. The evidence quality varies across studies, with some subgroup findings being uncertain due to smaller sample sizes than those available for GHD.

Evidence for Use in Adult Growth Hormone Deficiency ( AGHD)

For adults with Growth Hormone Deficiency ( AGHD), the research structure includes multiple placebo-controlled RCTs. These trials were used in research exploring short-term changes. Specifically, research examined changes in body composition, such as Lean Body Mass ( LBM) and Fat Mass, and monitored metabolic outcomes, including lipid profiles (e.g., cholesterol). Patient-reported outcomes describing perceived discomfort and quality of life ( QoL) were also measured. However, research limitations are noted. Long-term effects are not fully established; there is limited information from RCTs extending beyond five years that definitively addresses major clinical outcomes like fracture risk or cardiovascular events.

Common questions about Saizen (FAQ)

---

Q: What is the active substance in Saizen?

The active substance in Saizen is somatropin, which is a type of recombinant human growth hormone. According to the official product information, this substance is identical to the naturally occurring growth hormone produced in the body.

---

Q: Does Saizen come in a form for injection?

Yes, regulatory documents indicate that Saizen is available as a powder and solvent for solution for injection, as well as a pre-filled pen. The medicine is administered by subcutaneous injection, meaning it is injected under the skin.

---

Q: What happens if a dose of Saizen is missed?

Official product information advises that a missed dose is typically managed by injecting the next dose at the usual time the following day. The labeling states that a double dose should not be injected to compensate for a missed dose.

---

Q: Can Saizen be stored in the refrigerator before use?

Official information indicates that before reconstitution (mixing the powder), Saizen must be stored in a refrigerator at a temperature between 2°C and 8°C. It must be kept in the original container to protect it from light, according to regulatory documents.

---

Q: Is Saizen used to treat growth failure in children?

According to the official product information, Saizen is indicated for the treatment of growth failure in children due to specific conditions. These include growth hormone deficiency, Turner syndrome, and chronic renal failure.

---

Q: Is there a maximum time an already prepared solution of Saizen can be kept?

Regulatory documents state that once the powder has been reconstituted (mixed with the solvent), the prepared solution must be stored in the refrigerator. The maximum duration for which it can be kept varies based on the specific presentation of the medicine.

---

Q: Is Saizen also used for adults?

Yes, official product information confirms that Saizen is also indicated for the treatment of Adult Growth Hormone Deficiency (AGHD). This applies when the deficiency began in childhood or was acquired in adulthood due to pituitary or hypothalamic disease, or irradiation.

---

Q: Can Saizen affect blood sugar levels?

Studies and official information indicate that Saizen can affect how the body manages blood sugar, which is a key part of glucose metabolism. It may lead to a temporary resistance to the effects of insulin, the hormone that regulates sugar in the blood.

Saizen Storage and Disposal Requirements

Official regulatory guidelines strictly define how Saizen must be stored to maintain its stability. Unused cartridges and the reconstituted solution must be stored under refrigeration at mathbf2^circC to mathbf8^circC (mathbf36^circF to mathbf46^circF) and must not be frozen. The product must be stored in its original package to ensure protection from light.

After the first use, the cartridge is stable for a maximum of 28 days when refrigerated. It must be stored out of the sight and reach of children. All unused product, expired medicine, and waste materials, including used sharps, must be disposed of in accordance with local regulatory requirements using a puncture-proof container for needles.